peptide elongation factor 2 has been researched along with Intestinal Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bushell, M; Casey, HA; Cordero, JB; Dudek, KM; Faller, WJ; Hall, MN; Huels, DJ; Jackson, TJ; Jamieson, T; Jones, C; Karim, SA; Knight, JR; Meyuhas, O; Myant, KB; Pende, M; Radulescu, S; Ridgway, RA; Ryazanov, AG; Sansom, OJ; Scopelliti, A; Sonenberg, N; Vidal, M; Willis, AE | 1 |
1 other study(ies) available for peptide elongation factor 2 and Intestinal Neoplasms
| Article | Year |
|---|---|
mTORC1-mediated translational elongation limits intestinal tumour initiation and growth.
Topics: Adenomatous Polyposis Coli Protein; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Elongation Factor 2 Kinase; Enzyme Activation; Genes, APC; Intestinal Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Multiprotein Complexes; Oncogene Protein p55(v-myc); Peptide Chain Elongation, Translational; Peptide Elongation Factor 2; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Wnt Proteins | 2015 |